Pfizer Inc. Q1 2026 Earnings Recap

Pfizer's shares were little changed, rising 0.9% after earnings as the company's quarterly results and outlook broadly met market expectations without providing a clear catalyst for a larger move.

Key Takeaways

• Total revenues and adjusted diluted EPS exceeded internal expectations, supporting steady near-term financial performance.
• Launched and acquired products grew 22% operationally, with oncology (notably Seagen) achieving 20% year-over-year revenue growth.
• Nurtec contributed 41% operational growth, driven by strong demand across acute and preventive migraine treatments.
• Progress on R&D remains on track, with three positive Phase III readouts and plans for approximately 20 pivotal study starts in 2026.
• Legal developments, including Vyndamax patent settlements and a favorable Belgian court ruling on Comirnaty contracts, enhance long-term growth visibility and cash flow prospects.